山东步长制药股份有限公司第五届董事会第二十九次会议决议公告

Group 1 - The company held its 29th meeting of the fifth board of directors on August 15, 2025, where all 9 attending directors approved the agenda items [1][4] - The company’s subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., plans to sign a technology transfer contract with Shandong University of Traditional Chinese Medicine Hospital for the transfer of a traditional Chinese medicine formula for a total price of 15 million RMB [11][14] - The board approved the change of address for another subsidiary, Shandong Buchang Golden Key Pharmaceutical Technology Co., Ltd., due to operational management needs [5][26] Group 2 - The technology transfer agreement aims to enhance the company's product development pipeline and strengthen market competitiveness [21] - The financial data of Shandong Danhong as of December 31, 2024, shows total assets of 2.768 billion RMB, total liabilities of 1.487 billion RMB, and net assets of 1.281 billion RMB [18] - The financial data of Shandong University of Traditional Chinese Medicine Hospital as of June 30, 2025, indicates total assets of 5.570 billion RMB, total liabilities of 2.268 billion RMB, and net assets of 3.303 billion RMB [20]